Infectious Disease

Internal Medicine Sections Infectious Disease
GlobalRPh Clinical Pharmacy & Infectious Disease Resources

Infectious Disease, Antimicrobial Stewardship & Dosing Resource Center

Vancomycin and aminoglycoside pharmacokinetics, antimicrobial-resistance guidance, empiric-treatment references, pathogenic-bacteria databases, sepsis and ICU infection resources, HIV/STI/TB content, respiratory viruses and vaccines, antifungal therapy, C. difficile, renal dosing, IV dilution, and current GlobalRPh infectious-disease articles.

Vancomycin & PK AMR & stewardship Empiric therapy Internal Medicine Sections

Clinical background

Infectious-disease care requires the right drug, dose, duration, source control and reassessment

Antimicrobial therapy begins with a working diagnosis, but safe treatment also depends on infection site, likely pathogens, host factors, severity, prior antibiotics, allergies, organ function, local resistance patterns, source control, microbiologic data and the expected pharmacokinetic exposure at the site of infection. The initial regimen is therefore only the beginning of the decision process.

This updated portal brings together GlobalRPh’s pharmacokinetic calculators, Infectious Disease Database, bacterial-pathogen library, antimicrobial drug tables, renal dosing and IV dilution references with the much larger 2025–2026 article collection. Older empiric-treatment pages remain accessible while we progressively update their regimens, terminology and stewardship context.

Start appropriately Use syndrome, severity, exposure, host factors and local epidemiology to guide empiric therapy.
Measure what matters Cultures, susceptibility data, drug levels and renal function can materially change therapy.
Reassess early De-escalate, narrow, stop or modify therapy as diagnostic information and clinical response evolve.
Optimize exposure Dose, route, infusion duration, organ function and therapeutic drug monitoring affect efficacy and toxicity.
  • Antimicrobial pharmacokinetics
  • Antimicrobial resistance
  • Empiric syndrome-based therapy
  • Sepsis & ICU infection
  • HIV / STI / tuberculosis
  • Respiratory viruses & vaccines
  • Fungal / parasitic infection
  • C. difficile & microbiome
Infectious Disease Clinicians Managing A Critically Ill Patient
New GlobalRPh 2026 clinical tool

Vancomycin Dosing & Bayesian AUC Advanced Calculator

The new Advanced calculator combines conventional first-order pharmacokinetic AUC estimation with a model-informed Bayesian pathway, multiple adult population models, measured-concentration workflows, CRRT considerations, candidate regimens and clinician-directed AUC targeting. It is now the most advanced vancomycin tool in the GlobalRPh library.

Open the Vancomycin Advanced Calculator Read the Clinical Introduction

Foundational GlobalRPh resource

Infectious Disease Database & Pathogenic Bacteria

GlobalRPh already maintains a broad syndrome-based empiric-treatment index plus a separate microbiology database containing dozens of individual bacterial-pathogen pages. These resources are preserved as major destinations rather than duplicated in full on this landing page.

Open the Infectious Disease Database Open the Bacterial Pathogen Database

↑ Return to top Internal Medicine Sections

Antimicrobial pharmacokinetics & therapeutic drug monitoring

Vancomycin, aminoglycosides, levels and patient-specific dosing

Pharmacokinetics is one of GlobalRPh’s historic strengths. The revised portal places the newest vancomycin AUC calculator first while preserving the established aminoglycoside and level-based tools for clinicians who use those workflows.

Vancomycin AUC

Advanced PK & measured levels

Other dosing / safety tools

Several legacy vancomycin pages still contain trough-focused material from the pre-AUC era. The newest GlobalRPh Advanced calculator should be the preferred starting point for current AUC-guided workflows; older calculators remain available for comparison, historical use and specialized level-based workflows while their background sections are being refreshed.

Antimicrobial resistance & stewardship

Resistance-aware therapy is now central to the Infectious Disease portal

The current GlobalRPh article library has moved well beyond simple antibiotic-class tables. Recent material addresses pan-resistant gram-negative organisms, colistin, fosfomycin, MRSA, diagnostic stewardship and the expanding challenge of antimicrobial resistance.

Right indication Avoid treating colonization, contamination and nonbacterial syndromes as bacterial infection.
Right spectrum Use local epidemiology and patient-specific resistance risk, then narrow with microbiology.
Right exposure Optimize dose, interval, infusion strategy and organ-function adjustment.
Right duration Use syndrome- and response-based duration rather than automatically extending treatment.

Current GlobalRPh resistance reading

Current professional guidance

Resistance-focused GlobalRPh resources

↑ Return to top Internal Medicine Sections

Syndrome-based empiric therapy

GlobalRPh Infectious Disease Database

The GlobalRPh empiric-treatment database remains one of the largest internal resources in this section. The individual pages below are preserved as established references, while the portal distinguishes older regimens that are actively being updated.

Severe / hospital infection

Common outpatient / general infections

GI, wound & other syndromes

Many empiric-treatment pages were created before current resistance patterns, shorter-course evidence, newer antimicrobials and updated society guidance. They remain accessible because the syndrome/pathogen organization is useful, but regimen choice should be checked against current guidelines, local susceptibility data, allergies, organ function and prior antimicrobial exposure until each page completes our update process.

Microbiology

Pathogenic Bacteria Database

The previous Infectious Disease landing page printed more than 70 pathogen links in one long list. The redesigned portal makes the full database a primary destination and surfaces selected high-yield organisms below.

Browse the Complete GlobalRPh Pathogenic Bacteria Database

Acinetobacter baumannii Bacteroides fragilis Bordetella pertussis Enterococcus faecium Escherichia coli Klebsiella species Legionella species Listeria monocytogenes Neisseria species Pseudomonas aeruginosa Staphylococcus aureus / MRSA Stenotrophomonas maltophilia Streptococcus pneumoniae Streptococcus pyogenes Treponema pallidum Gram-Negative Bacteria Index
The complete database contains dozens of additional pathogens

The full GlobalRPh bacterial database includes Achromobacter, Actinomyces, Aeromonas, Bartonella, Borrelia, Brucella, Burkholderia, Campylobacter, Capnocytophaga, Chlamydophila, Clostridium, Corynebacterium, Coxiella, Ehrlichia, Enterobacter, Francisella, Fusobacterium, Haemophilus, Helicobacter, Leptospira, Moraxella, Morganella, Mycoplasma, Nocardia, Pasteurella, Proteus, Providencia, Rickettsia, Salmonella, Serratia, Shigella, Vibrio and many others.

Open the complete bacterial-pathogen index

↑ Return to top Internal Medicine Sections

Sepsis & critical infection

Source identification, timely therapy and reassessment

Sepsis belongs at the intersection of Infectious Disease, Critical Care and antimicrobial stewardship. The updated portal links GlobalRPh’s existing sepsis page to the 2026 Surviving Sepsis Campaign rather than allowing older SIRS-era language to stand alone.

GlobalRPh sepsis resources

Current sepsis guidance

Source / dosing support

HIV, sexually transmitted infections & tuberculosis

Current clinical guidance plus established GlobalRPh medication resources

HIV

STIs

Tuberculosis

The GlobalRPh gonorrhea treatment page contains older ceftriaxone dosing and dual-therapy regimens. It remains linked for historical continuity, but the current CDC STI guidance should be used until that page is rebuilt.
↑ Return to top Internal Medicine Sections

Respiratory viruses, vaccines & emerging infection

RSV, influenza, hMPV, avian influenza, mRNA vaccines and polio

Respiratory viruses

Vaccines & prevention

Preparedness & surveillance

C. difficile & microbiome therapeutics

From historical metronidazole regimens to recurrent-infection microbiome therapy

GlobalRPh clinical resources

Newer recurrent-infection content

Current guideline verification

The older GlobalRPh C. difficile page still presents metronidazole as an initial treatment option. We plan to rebuild it around current fidaxomicin/vancomycin strategies, recurrence prevention, bezlotoxumab where relevant, FDA-approved microbiota products, fecal microbiota approaches and antimicrobial stewardship.
↑ Return to top Internal Medicine Sections

Fungal, parasitic & opportunistic infection

Antifungals, protozoal therapy and immunocompromised-host crossover

Systemic antifungals

Parasitic / protozoal therapy

Immunocompromised host

Antimicrobial pharmacotherapy

GlobalRPh infectious-disease drug tables

The existing portal’s antimicrobial class library is preserved and organized below by therapeutic family. The broader Infectious Disease Drug List provides the complete index.

Antibacterial classes

Antiviral / mycobacterial / vaccine

Fungal / topical / other

Browse the Complete Infectious Disease Drug List

↑ Return to top Internal Medicine Sections

GlobalRPh infectious-disease article library

Current antimicrobial, viral, vaccine and public-health reading

The older portal exposed only a small handful of articles. This section brings forward a much larger 2025–2026 Infectious Disease library.

2026

GlobalRPh Vancomycin Dosing and Bayesian AUC Advanced Calculator Vancomycin • AUC • Bayesian pharmacokinetics • Clinical dosing RSV Monoclonal Antibodies: A Paradigm Shift in Infant Protection RSV • Nirsevimab • Clesrovimab • Infant prevention The Changing Geography of Sexually Transmitted Infections in the United States STI surveillance • Syphilis • Gonorrhea • HIV • Public health The Rise of Pan-Resistant Gram-Negatives AMR • CRE • CRAB • Pseudomonas • Stewardship Microbiome Therapeutics After Recurrent C. diff C. difficile • Recurrence • Microbiota-based therapy The Return of Old Antibiotics: Colistin and Fosfomycin Multidrug resistance • Colistin • Fosfomycin • Toxicity Antibiotics for H. pylori: Why First-Line Treatment Fails H. pylori • Resistance • Salvage therapy • Gastroenterology Vancomycin for MRSA: Why Clinicians Are Reconsidering the Gold Standard MRSA • Vancomycin • Linezolid • Site-specific therapy mRNA Vaccines Beyond COVID-19 Vaccines • mRNA technology • Infectious disease prevention Why Diagnostic Stewardship in the ED Reduces Medical Errors Blood cultures • Rapid diagnostics • Stewardship • Sepsis
2025

Treatment for Latent TB: Critical Steps Internists Often Miss Latent TB • Rifamycin regimens • Screening • Prevention The RSV Vaccine for Adults RSV vaccination • Older adults • Prevention Managing HIV in Primary Care HIV • ART • Primary care • Opportunistic infection prevention H. pylori: When Antibiotics Stop Working Antibiotic resistance • H. pylori • Treatment failure Global Polio Resurgence Polio • Vaccination • Surveillance • Global health Universal Influenza Vaccines Influenza • Vaccine development • Prevention Superbugs: New Therapies for Antibiotic-Resistant Bacterial Infections AMR • Novel antibiotics • Alternative therapy Respiratory Syncytial Virus (RSV) RSV • Prevention • Clinical management Top 20 Contagious Diseases in the United States Epidemiology • Public risk • Prevention Emerging Threats: Avian Influenza and hMPV H5N1 • hMPV • Emerging respiratory infection
Infectious Disease Articles Infectious Disease Calculators Empiric Therapy Database

GlobalRPh infectious-disease video library

Existing infectious-disease videos

Vancomycin

Vancomycin Dosing & Therapeutic Drug Monitoring

STIs

Recent Trends in STDs – Herpes & Syphilis

hMPV

hMPV Outbreak Data & Transmission Patterns

Avian influenza

Avian Influenza – H5N1 & H7N9

Norovirus

Norovirus – Symptoms, Treatment & Prevention

RSV

RSV Explained

Influenza

Influenza Review & Management

Contagious disease

Top 20 Contagious Diseases in the U.S.

GlobalRPh Video Library Infectious Disease Articles Stewardship Articles
↑ Return to top Internal Medicine Sections

Planned GlobalRPh updates

Areas we’re continuing to improve in the Infectious Disease library

The GlobalRPh Infectious Disease section contains some of our oldest clinical pages as well as some of our newest tools. Antimicrobial resistance, dosing targets, drug availability, recommended treatment duration and stewardship principles have changed substantially. As we work through this section, we plan to preserve the useful databases while updating the clinical recommendations and medication details page by page.

Pages we plan to refresh

  • Vancomycin legacy calculators: our new 2026 Advanced AUC/Bayesian tool is now the preferred modern platform. We plan to update or consolidate older pages that still emphasize 2009 trough targets, clearly distinguish AUC-based and legacy workflows, and keep specialized measured-level tools where they still add value.
  • Infectious Disease – Drug of Choice: this page contains a useful syndrome structure but an older reference base. We plan to rebuild it around current society guidance, resistance patterns, stewardship and the existing GlobalRPh empiric-therapy database.
  • Sepsis – Unknown Source: we plan to replace SIRS-era explanatory language, remove fixed one-size-fits-all empiric regimens, add source- and resistance-risk assessment, and connect treatment timing and reassessment to the 2026 Surviving Sepsis Campaign.
  • CAP / HAP / VAP: we plan to update antimicrobial selection, current duration principles, MRSA/Pseudomonas risk, local antibiogram use, de-escalation and diagnostic stewardship. The VAP page’s older vancomycin trough goal will be replaced with current AUC-guided context.
  • Gonorrhea / STI pages: we plan to replace older ceftriaxone doses and dual-therapy regimens with current CDC treatment, partner-management and screening guidance, while adding resistance-surveillance context.
  • C. difficile: we plan to replace the older metronidazole-centered framework with current fidaxomicin/vancomycin strategies, recurrence prevention and microbiome-based therapies.
  • Endocarditis: we plan to update prophylaxis criteria, remove outdated GI/GU prophylaxis concepts and obsolete clindamycin prophylaxis language, and modernize organism- and valve-specific treatment links.
  • UTI / pyelonephritis: we plan to update uncomplicated versus complicated infection, asymptomatic bacteriuria, culture thresholds, resistance risk, duration, recurrent UTI pathways and newer oral/IV options.
  • Cellulitis / SSTI: we plan to update nonpurulent versus purulent disease, abscess/source control, MRSA coverage, duration, severe infection and diabetic/immunocompromised pathways.
  • Meningitis: we plan to update age/risk-based empiric therapy, dexamethasone context, resistant pneumococcus, Listeria coverage, diagnostic testing and pathogen-specific therapy.
  • Colistin Dosing Calculator: the current tool remains labeled BETA. We plan to re-check units, colistin base activity versus colistimethate labeling, renal replacement therapy, international dosing conventions and its modern role relative to newer agents.
  • Desensitization protocol: we plan to update agent selection, allergy verification, contraindications, monitoring and the distinction between true IgE-mediated allergy, intolerance and unnecessary penicillin-allergy labels.
  • HIV antiretroviral table: we plan to rebuild this around current first-line regimens, long-acting therapy, resistance testing, pregnancy, renal/hepatic considerations, drug interactions and the current NIH guidelines.
  • Tuberculosis agents: we plan to incorporate the 2025 ATS/CDC/ERS/IDSA treatment update, short-course latent-TB regimens, current drug-resistant TB therapy and modern monitoring.
  • Anti-influenza agents: the current table still contains amantadine/rimantadine influenza-treatment material. We plan to update currently recommended antivirals, resistance, renal dosing, high-risk treatment and current CDC/IDSA seasonal guidance.
  • Immunizations: we plan to make current CDC schedules the primary framework and update RSV, COVID-19, influenza, pneumococcal, shingles, meningococcal and travel-related recommendations without hard-coding a schedule that can become obsolete.
  • Antifungal tables: we plan to verify currently marketed agents, new azoles/antifungals, therapeutic-drug-monitoring needs, interactions, renal/hepatic considerations and the newly updated 2026 aspergillosis guidance.
  • Bacterial pathogen pages: we plan to preserve the microbiology database but progressively update taxonomy, resistance mechanisms, current treatment options and obsolete antibiotic recommendations organism by organism.
Modern empiric-therapy selector Evaluate syndrome, allergies, renal function and resistance-risk inputs with current guideline links.
Antibiotic timeout tool Support 48–72-hour reassessment: indication, cultures, spectrum, route, dose and duration.
Penicillin-allergy pathway Evaluate risk stratification and de-labeling decision support linked to desensitization only when appropriate.
C. difficile recurrence tool Organize episode number, severity, recurrence risk and microbiome-treatment options.
Antimicrobial renal-dose dashboard Connect high-use antimicrobials with current renal dosing and dialysis/CRRT considerations.
AMR organism navigator Link ESBL, AmpC, CRE, DTR Pseudomonas, CRAB and Stenotrophomonas to current IDSA guidance.
Our goal is not to erase GlobalRPh’s longstanding Infectious Disease database. We plan to preserve its practical organization while replacing outdated regimens, updating antimicrobial pharmacology and making current stewardship and resistance guidance easier to reach.

Current external clinical guidance

Primary infectious-disease, stewardship and public-health resources

Infectious Disease changes rapidly because resistance patterns, outbreak epidemiology, vaccine schedules and therapeutic options evolve continuously. These primary sources provide current verification while individual GlobalRPh pages are being refreshed.

IDSA Practice Guideline Library Current and archived IDSA guidance across bacterial, viral, fungal, parasitic and antimicrobial-stewardship topics. Open IDSA guidelines
IDSA 2026 Antimicrobial-Resistant Gram-Negative Guidance Current guidance for ESBL-E, AmpC-E, CRE, DTR Pseudomonas, CRAB and Stenotrophomonas maltophilia. Open 2026 AMR guidance
CDC Antibiotic Stewardship Core Elements Current hospital, outpatient, nursing-home and health-system stewardship frameworks. Open CDC stewardship resources
2026 Surviving Sepsis Campaign – Adults Current international adult sepsis and septic-shock management recommendations. Open 2026 adult sepsis guidance
NIH HIV Clinical Guidelines Federally approved, continuously updated guidance for antiretroviral therapy and opportunistic infections. Open NIH HIV guidelines
CDC STI Clinical Guidance Current CDC prevention, diagnostic, screening and treatment guidance for sexually transmitted infections. Open CDC STI guidance
CDC Tuberculosis Clinical Guidelines Includes the 2025 ATS/CDC/ERS/IDSA update for drug-susceptible and drug-resistant tuberculosis. Open CDC TB guidance
CDC Immunization Schedules Current child/adolescent and adult immunization schedules with ongoing updates. Open CDC immunization schedules
IDSA 2026 Invasive Aspergillosis Prevention New 2026 IDSA recommendations for prevention of invasive aspergillosis in adult solid-organ transplant recipients. Open aspergillosis guidance
CDC Clinical Care & Outbreak Resources Current public-health pages for respiratory infections, vaccines, TB, STIs, healthcare-associated infection and antimicrobial resistance. Open CDC

Supporting GlobalRPh resources

Critical care, organ-function, dilution and specialty cross-links

Hospital / dosing support

Related specialty portals

Laboratory & directories

Why older empiric-treatment pages remain linked during the update process

The syndrome-based organization of the GlobalRPh Infectious Disease Database remains useful, and many pages are linked from search engines and other GlobalRPh sections. We are preserving those URLs while modernizing the regimens, stewardship principles, resistance assumptions and current drug information instead of removing the material before replacement content is ready.

↑ Return to top Internal Medicine Sections

Clinical use: GlobalRPh antimicrobial calculators, empiric-treatment pages, pathogen references, drug tables and educational articles are intended to support, not replace, current susceptibility data, product labeling, local antibiograms, source control, microbiologic testing, guideline-based care, therapeutic drug monitoring, institutional protocols, infectious-disease consultation when indicated and professional judgment. Antimicrobial therapy should be individualized to infection site, severity, likely and confirmed pathogens, allergies, organ function, prior exposure, resistance risk, drug interactions and clinical response.

Return to Internal Medicine Sections  |  Empiric Therapy  |  Pathogenic Bacteria  |  Pharmacokinetics  |  Renal Dosing

↑ Return to the top of the Infectious Disease page

Alphabetical Listing of individual drugs

abcdefghijklm
nopqrstuvwxyz

Common LAB Values  Renal Dosing

Internal Medicine Sections